InvestorsHub Logo
Followers 839
Posts 120481
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 1794

Thursday, 11/21/2019 4:09:40 PM

Thursday, November 21, 2019 4:09:40 PM

Post# of 3205
ENTA FY4Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Fourth-Quarter-and-Year-Ended-September-30-2019/default.aspx

FY4Q19 royalty revenue=$51.3M, up from $44.4M in FY3Q19 (Apr-Jun 2019).

ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.

9/30/19 cash=$400M.

FY4Q19 GAAP EPS=$0.44.

FY2020 R&D guidance is $155-175M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News